Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 15 Jun 2023 for Mimedx Group, INC., €162k.
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Phyllis Gardner: trading record in brief
Phyllis Gardner (board member) discloses dealings in 3 companies, chiefly Revance Therapeutics, Inc., Mimedx Group, Inc. and Corium International, Inc. We count 18 filings; the first trade dates from 11 February 2014 and the latest from 13 June 2023.
No open-market purchase appears, only 1 sale worth €137k. Outside the open market, there are 10 share grants and 4 option exercises.
Most recently, on 15 June 2023, the filings show a share grant worth €162k in Mimedx Group, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Phyllis Gardner
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
35,354 shares@ US$4.9526.5% of flowCommon StockSEC:0001376339-23-000040:0
44,191 shares@ US$3.960.016% mcap36.3% of flowCommon StockSEC:0001376339-22-000091:0
17,056 shares@ US$10.2630.6% of flowCommon StockSEC:0001376339-21-000075:0
3 of 3 declarations
